Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma

Journal of Hepatology

Volumn 56, Issue 2, 2012, Pages 406-411

  Shim, Ju Hyun ^a   Lee, Han Chu ^a   Won, Hyung Jin ^b   Shin, Yong Moon ^b   Kim, Kang Mo ^a   Lim, Young Suk ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

European Association for the Study of the Liver (EASL) criteria; Hepatocellular carcinoma; Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria; Target lesion; Transarterial chemoembolization

Indexed keywords

CISPLATIN; GELFOAM; IOPROMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT TOOL; DRUG RESPONSE; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER CRITERIA; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ENDPOINT DETERMINATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84855973043     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.04.028     Document Type: Article

References (12)

1. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214 (Pubitemid 11167383)
2. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
3. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
4. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
5. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
6. D. Warr, S. McKinney, and I. Tannock Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response J Clin Oncol 2 1984 1040 1046 (Pubitemid 14026263)
7. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
8. B.I. Choi, H.C. Kim, J.K. Han, J.H. Park, Y.I. Kim, and S.T. Kim Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings Radiology 182 1992 709 713
9. D. Altman Practical statistics for medical research 1991 Chapman and Hall London
10. K.D. Hopper, C.J. Kasales, M.A. Van Slyke, T.A. Schwartz, T.R. TenHave, and J.A. Jozefiak Analysis of interobserver and intraobserver variability in CT tumor measurements AJR Am J Roentgenol 167 1996 851 854 (Pubitemid 26322230)
11. P. Thiesse, L. Ollivier, D. Di Stefano-Louineau, S. Negrier, J. Savary, and K. Pignard Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer J Clin Oncol 15 1997 3507 3514
12. A. Riaz, F.H. Miller, L.M. Kulik, P. Nikolaidis, V. Yaghmai, and R.J. Lewandowski Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069